Abstract:Objective: To develop a Verapamil hydrochloride controlled release gastro-retentive (CRGR) tablet for once-daily dosing using the response surface Box-Behnken Design (BBD) approach for the improvement of bioavailability and reduction in dosing frequency to overcome the issues related to the conventional tablet formulation. Methods: For the optimization, 33Box-Behnken design was used. The independent variables were selected, the amount of Compritol 888 ATO (A), HPMC K15M (B), and Sodium bicarbonate (C). The dependent variables were Cumulative % drug release in 1.5 h (Q1.5), 8 h (Q8), 24 H (Q24) and floating lag time (FLT). Flow properties of pre-compressed powder, physical characteristics, drug content, floating lag time, total floating time and in vitro dissolution study of all formulation were assessed. In vitro dissolution study of optimized formulation that was prepared experimentally was performed and compared with predicted data obtained from the software. Drug release kinetics of the optimized formulation was also assessed to know the mechanism of drug release from the CRGR tablets. Results: Responses of experimental runs were found as Q1.5: 12.78-33.62 (%), Q8: 43.03-64 (%), Q24: 78.77 to 103.57 (%) and floating lag time as 3.01 min to 5.08 min. The predicted optimized formula with the highest desirability value of 0.963 containing amount 126.030 mg, 160.00 mg and 80.955 mg of Compritol 888 ATO, HPMC K15M and Sodium biarbonate respectively was prepared and evaluated. The experimental values from optimized formulation were obtained as Q1.5: 23.397%, Q8; 57.744%, Q24: 97.150% and FLT: 3.12 min. Predicted and experimental results were found comparable for all the responses. The release data from the optimized formulation were best fitted in the Higuchi (r2 = 0.999) and the Korsmeyer-Peppas ((r2 = 0.998, n=0.54) model. The in vitro drug release studies indicated that the Verapamil hydrochloride gastroretentive tablet releases the drug in controlled manner for 24 h. Conclusion: This study found that using Box-Behnken Design with the response and variable relation, it is possible to achieve an optimum formulation with desirable characteristics. This study also established the suitability of Compritol 888 ATO-HPMC K15M combination with Sodium bicarbonate to increase the gastric residence time tablet formulation had once-daily dosing of the Verapamil Hcl with improved bioavailability for effective management of hypertension.

Application of Gray Absolute Degree of Incidence to Formulation Optimization of Delayed, Sustained-release Propranolol Hydrochloride Pellets

Delayed Sustained Drug Release from Electrostatic Powder Coated Tablets with Ultrafine Polymer Blends

Study on pramipexole dihydrochloride sustained-release tablets

Preparation of Captopril Delayed-Onset, Sustained Release Tablets

Preparation of Sustained Release Capsules by Electrostatic Dry Powder Coating, Using Traditional Dip Coating As Reference

Preparation and Evaluation of a Novel Delayed-Onset Sustained-Release System of Propranolol Hydrochloride

Optimization of Gastroretentive Delayed Release Drug Delivery using Design of Experiment Approach

Optimization of Breviscapin Sustainded Release Tablets by Mixture Uniform Design

BOX-BEHNKEN DESIGN FOR OPTIMIZATION OF FORMULATION VARIABLES FOR CONTROLLED RELEASE GASTRORETENTIVE TABLET OF VERAPAMIL HYDROCHLORIDE

Optimization of Preparation Process and Pharmacokinetics of APAP Double-Release Pellet Capsules

Formulation Optimization of Zuojin Floating-Bioadhesive Pellets by Central Composite Design-Response Surface Methodology

Study on the Optimal Formulation and Preparation Conditions of Propranolol-loaded Transfersomes by Central Composite Design and Response Surface Method

Application of the custom design methodology in the buflomedil hydrochloride sustained release tablets formulation

Optimization of ticagrelor tablet for gastro-retentive drug delivery using full factorial design

Formulation and Evaluation of Delayed Release Pellets of Ivabradine Hydrochloride

Blends of Hydrophobic and Swelling Agents in the Swelling Layer in the Preparation of Delayed-Release Pellets of a Hydrophilic Drug with Low MW: Physicochemical Characterizations and In-Vivo Evaluations

Comparison of Several Statistic Designs in the Development of Ligustrazine Hydrochloride(tmph) Sustained Release Formulations

Influence of Prunus domestica gum on the release profiles of propranolol HCl floating tablets.

Optimization of formulation for the Qiyuejiangzhi tablets

Investigation of Formulation and in-Process Parameters of Clopidogrel Bisulfate Tablets

Preparation of Double Pulse Control Release Pellets of Zolpidem Tartrate